AVCN.TO
Avicanna Inc. [AVCN.TO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AVCN.TO Stock Summary
Top 10 Correlated ETFs
AVCN.TO
Top 10 Correlated Stocks
AVCN.TO
In the News
AVCN.TO Financial details
Company Rating
Sell
Market Cap
35.08M
Income
-8.24M
Revenue
16.79M
Book val./share
-0
Cash/share
0.01
Dividend
-
Dividend %
-
Employees
80
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-2.32
Forward P/E
-
PEG
0.35
P/S
2.58
P/B
29.75
P/C
39
P/FCF
-15.73
Quick Ratio
0.28
Current Ratio
0.64
Debt / Equity
-15.18
LT Debt / Equity
-
-
-
EPS (TTM)
-0.1
EPS next Y
-
EPS next Q
-
EPS this Y
-67.9%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-39.08%
Revenue last 5Y
151.09%
Revenue Q/Q
-3.19%
EPS Q/Q
74.23%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.01%
Inst Trans
0%
ROA
-53%
ROE
-1656%
ROC
-1.47%
Gross Margin
25%
Oper. Margin
-89%
Profit Margin
-111%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.23-0.6
52W High
-
52W Low
-
RSI
41
Rel Volume
0.06
Avg Volume
94.24K
Volume
5.56K
Perf Week
-6.02%
Perf Month
-19.59%
Perf Quarter
-7.14%
Perf Half Y
-18.75%
-
-
-
-
Beta
1.504
-
-
Volatility
0.02%, 0.06%
Prev Close
2.63%
Price
0.39
Change
-8.24%
AVCN.TO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0.05 | 0.08 | 0.07 | 0.2 | |
| Net income per share | -1.11 | -1.12 | -0.41 | -0.29 | -0.09 | |
| Operating cash flow per share | -0.97 | -0.48 | -0.28 | -0.13 | -0.02 | |
| Free cash flow per share | -1.34 | -0.52 | -0.3 | -0.13 | -0.02 | |
| Cash per share | 0.02 | 0.09 | 0 | 0.02 | 0.01 | |
| Book value per share | 1.12 | 0.2 | 0.03 | -0.01 | 0 | |
| Tangible book value per share | 0.78 | 0.46 | 0.16 | 0.06 | 0.09 | |
| Share holders equity per share | 1.12 | 0.2 | 0.03 | -0.01 | 0 | |
| Interest debt per share | 0.07 | 0.07 | 0.06 | 0.08 | 0.03 | |
| Market cap | 50.94M | 38.51M | 32.2M | 24.26M | 29.65M | |
| Enterprise value | 51.77M | 39.18M | 33.83M | 26.27M | 30.97M | |
| P/E ratio | -2.29 | -1.17 | -1.92 | -1.41 | -3.76 | |
| Price to sales ratio | 302.74 | 24.53 | 9.85 | 5.99 | 1.77 | |
| POCF ratio | -2.62 | -2.76 | -2.76 | -3.26 | -21.11 | |
| PFCF ratio | -1.89 | -2.5 | -2.59 | -3.23 | -15.11 | |
| P/B Ratio | 2.28 | 6.4 | 28.1 | -63.25 | -263.53 | |
| PTB ratio | 2.28 | 6.4 | 28.1 | -63.25 | -263.53 | |
| EV to sales | 307.67 | 24.95 | 10.35 | 6.49 | 1.84 | |
| Enterprise value over EBITDA | -2.37 | -2.25 | -3.4 | -2.71 | -4.49 | |
| EV to operating cash flow | -2.66 | -2.8 | -2.9 | -3.53 | -22.06 | |
| EV to free cash flow | -1.92 | -2.54 | -2.72 | -3.5 | -15.79 | |
| Earnings yield | -0.44 | -0.85 | -0.52 | -0.71 | -0.27 | |
| Free cash flow yield | -0.53 | -0.4 | -0.39 | -0.31 | -0.07 | |
| Debt to equity | 0.06 | 0.32 | 1.45 | -8.37 | -15.18 | |
| Debt to assets | 0.03 | 0.06 | 0.07 | 0.18 | 0.08 | |
| Net debt to EBITDA | -0.04 | -0.04 | -0.16 | -0.21 | -0.19 | |
| Current ratio | 0.45 | 0.53 | 0.6 | 0.62 | 0.71 | |
| Interest coverage | -415.81 | -70.44 | -14.68 | -6.33 | -12.58 | |
| Income quality | 0.88 | 0.43 | 0.7 | 0.5 | 0.18 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 122 | 10.07 | 3.83 | 2.37 | 0 | |
| Research and developement to revenue | 7.23 | 0.24 | 0.09 | 0.07 | 0.02 | |
| Intangibles to total assets | 0.32 | 0.02 | 0.01 | 0.01 | 0.02 | |
| Capex to operating cash flow | 0.39 | 0.1 | 0.07 | 0.01 | 0.4 | |
| Capex to revenue | -44.51 | -0.93 | -0.24 | -0.02 | -0.03 | |
| Capex to depreciation | -8.11 | -1.34 | -0.88 | -0.08 | -0.72 | |
| Stock based compensation to revenue | 15.96 | 1.98 | 0.4 | 0.26 | 0 | |
| Graham number | 5.27 | 2.27 | 0.5 | 0.21 | 0.05 | |
| ROIC | -0.9 | -2.09 | -3.66 | -3.87 | -4.1 | |
| Return on tangible assets | -0.72 | -1.11 | -0.76 | -0.99 | -0.36 | |
| Graham Net | -0.66 | -0.41 | -0.28 | -0.16 | -0.11 | |
| Working capital | -4.77M | -6.05M | -4.84M | -4.34M | -3.51M | |
| Tangible asset value | 15.6M | 13.41M | 6.61M | 3.29M | 7.64M | |
| Net current asset value | -11.34M | -9.48M | -8.04M | -7.1M | -5.54M | |
| Invested capital | 0.06 | 0.32 | 1.45 | -8.37 | -15.18 | |
| Average receivables | 730.77K | 1.1M | 1.67M | 2.24M | 2.56M | |
| Average payables | 3.32M | 5.87M | 6.93M | 6.02M | 6.81M | |
| Average inventory | 874.37K | 1.76M | 3.01M | 3.66M | 3.89M | |
| Days sales outstanding | 2.61K | 233.7 | 260.81 | 193.81 | 64.52 | |
| Days payables outstanding | 24.83K | 1.12K | 6.09K | 591.56 | 317.15 | |
| Days of inventory on hand | 7.68K | 328.62 | 3.41K | 403.27 | 162.48 | |
| Receivables turnover | 0.14 | 1.56 | 1.4 | 1.88 | 5.66 | |
| Payables turnover | 0.01 | 0.33 | 0.06 | 0.62 | 1.15 | |
| Inventory turnover | 0.05 | 1.11 | 0.11 | 0.91 | 2.25 | |
| ROE | -0.99 | -5.46 | -14.64 | 44.89 | 70.09 | |
| Capex per share | -0.37 | -0.05 | -0.02 | 0 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.02 | 0.02 | 0.04 | 0.07 | 0.07 | |
| Net income per share | -0.1 | -0.03 | -0.02 | -0.02 | -0.03 | |
| Operating cash flow per share | -0.01 | -0.03 | -0.01 | 0.03 | -0.01 | |
| Free cash flow per share | -0.01 | -0.03 | -0.02 | 0.03 | -0.01 | |
| Cash per share | 0.02 | 0 | 0 | 0.01 | 0.01 | |
| Book value per share | -0.01 | 0.02 | 0.02 | 0.01 | 0 | |
| Tangible book value per share | 0.04 | 0.06 | 0.06 | 0.04 | 0.08 | |
| Share holders equity per share | -0.01 | 0.02 | 0.02 | 0.01 | 0 | |
| Interest debt per share | 0.05 | 0.03 | 0.02 | 0.03 | 0.02 | |
| Market cap | 30.73M | 31.84M | 25.89M | 40.09M | 31.74M | |
| Enterprise value | 32.75M | 33.42M | 27.53M | 41.5M | 33.06M | |
| P/E ratio | -1.02 | -3.22 | -3.68 | -7.04 | -3.08 | |
| Price to sales ratio | 27.05 | 27.21 | 7.81 | 6.41 | 5.24 | |
| POCF ratio | -35.38 | -15.52 | -22.1 | 14.96 | -36.89 | |
| PFCF ratio | -34.62 | -15.39 | -18.12 | 16.47 | -35.32 | |
| P/B Ratio | -80.12 | 27.14 | 18.98 | 39.1 | -282.1 | |
| PTB ratio | -80.12 | 27.14 | 18.98 | 39.1 | -282.1 | |
| EV to sales | 28.82 | 28.56 | 8.31 | 6.64 | 5.46 | |
| Enterprise value over EBITDA | -6.45 | -15.45 | -18.37 | -39.38 | -16.76 | |
| EV to operating cash flow | -37.7 | -16.29 | -23.51 | 15.49 | -38.43 | |
| EV to free cash flow | -36.89 | -16.16 | -19.27 | 17.05 | -36.8 | |
| Earnings yield | -0.24 | -0.08 | -0.07 | -0.04 | -0.08 | |
| Free cash flow yield | -0.03 | -0.06 | -0.06 | 0.06 | -0.03 | |
| Debt to equity | -8.37 | 1.54 | 1.29 | 2.08 | -15.18 | |
| Debt to assets | 0.18 | 0.1 | 0.08 | 0.09 | 0.08 | |
| Net debt to EBITDA | -0.4 | -0.73 | -1.1 | -1.34 | -0.67 | |
| Current ratio | 0.62 | 0.67 | 0.72 | 0.64 | 0.71 | |
| Interest coverage | -15.14 | -10.53 | -16.38 | -9.51 | -14.36 | |
| Income quality | 0.13 | 0.82 | 0.67 | -1.88 | 0.33 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 2.21 | 2.22 | 0.83 | 0.51 | 0 | |
| Research and developement to revenue | 0.08 | 0.09 | 0.01 | 0.01 | 0.02 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.02 | 0.07 | 0.02 | |
| Capex to operating cash flow | 0.02 | 0.01 | 0.22 | -0.09 | 0.04 | |
| Capex to revenue | -0.02 | -0.01 | -0.08 | -0.04 | -0.01 | |
| Capex to depreciation | -0.11 | -0.1 | -1.61 | -1.05 | -0.17 | |
| Stock based compensation to revenue | 0.21 | 0.85 | 0.15 | 0.08 | 0 | |
| Graham number | 0.11 | 0.11 | 0.09 | 0.07 | 0.03 | |
| ROIC | -1.88 | -0.69 | -0.57 | -0.43 | -1.1 | |
| Return on tangible assets | -0.43 | -0.14 | -0.08 | -0.06 | -0.12 | |
| Graham Net | -0.13 | -0.12 | -0.13 | -0.15 | -0.1 | |
| Working capital | -4.34M | -3.38M | -4.09M | -6.35M | -3.51M | |
| Tangible asset value | 3.29M | 4.75M | 4.92M | 3.3M | 7.64M | |
| Net current asset value | -7.1M | -5.96M | -6.49M | -8.57M | -5.54M | |
| Invested capital | -8.37 | 1.54 | 1.29 | 2.08 | -15.18 | |
| Average receivables | 2.46M | 2.3M | 3.42M | 4.29M | 3.58M | |
| Average payables | 4.36M | 4.72M | 6.41M | 8.69M | 9.06M | |
| Average inventory | 4.44M | 3.34M | 4.32M | 5.43M | 5.11M | |
| Days sales outstanding | 170.27 | 189.01 | 119.02 | 60.3 | 44.13 | |
| Days payables outstanding | 139.75 | 724.85 | 400.69 | 245.6 | 202.32 | |
| Days of inventory on hand | 95.27 | 531.23 | 255.86 | 150.66 | 103.65 | |
| Receivables turnover | 0.53 | 0.48 | 0.76 | 1.49 | 2.04 | |
| Payables turnover | 0.64 | 0.12 | 0.22 | 0.37 | 0.44 | |
| Inventory turnover | 0.94 | 0.17 | 0.35 | 0.6 | 0.87 | |
| ROE | 19.55 | -2.11 | -1.29 | -1.39 | 22.91 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
AVCN.TO Frequently Asked Questions
What is Avicanna Inc. stock symbol ?
Avicanna Inc. is a CA stock , located in Toronto of On and trading under the symbol AVCN.TO
What is Avicanna Inc. stock quote today ?
Avicanna Inc. stock price is $0.39 today.
Is Avicanna Inc. stock public?
Yes, Avicanna Inc. is a publicly traded company.
Company Profile
- Volume Average 94.24K
- Market Capitalization 35.08M
- Employee 80
- CEO Mr. Aras Azadian B.Econ, Mba
- Headquarters Toronto,ON,CA
- IPO Date 2019-07-18
-
Website
https://www.avicanna.com 
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
